Union Savings Bank Sells 405 Shares of Novo Nordisk A/S (NYSE:NVO)

Union Savings Bank lowered its stake in Novo Nordisk A/S (NYSE:NVO) by 5.7% during the 4th quarter, Holdings Channel reports. The institutional investor owned 6,659 shares of the company’s stock after selling 405 shares during the quarter. Union Savings Bank’s holdings in Novo Nordisk A/S were worth $573,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Natixis Advisors LLC raised its holdings in Novo Nordisk A/S by 2.7% during the third quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock valued at $366,125,000 after acquiring an additional 80,070 shares during the period. Norman Fields Gottscho Capital Management LLC boosted its stake in Novo Nordisk A/S by 45.3% in the 4th quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock worth $5,482,000 after purchasing an additional 19,870 shares during the period. Talbot Financial LLC purchased a new stake in Novo Nordisk A/S during the 4th quarter valued at approximately $4,066,000. Versant Capital Management Inc bought a new stake in shares of Novo Nordisk A/S during the fourth quarter valued at approximately $86,000. Finally, Zions Bancorporation N.A. lifted its holdings in shares of Novo Nordisk A/S by 57.0% in the third quarter. Zions Bancorporation N.A. now owns 18,535 shares of the company’s stock worth $2,207,000 after buying an additional 6,726 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Price Performance

Shares of NYSE:NVO opened at $78.74 on Monday. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. Novo Nordisk A/S has a twelve month low of $78.17 and a twelve month high of $148.15. The company’s 50 day moving average is $97.76 and its 200 day moving average is $117.05. The company has a market cap of $353.33 billion, a PE ratio of 25.48, a price-to-earnings-growth ratio of 0.92 and a beta of 0.45.

Analyst Ratings Changes

Several research analysts have commented on the stock. BMO Capital Markets dropped their price objective on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, December 23rd. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. Cantor Fitzgerald restated an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Finally, BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $140.20.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.